Showing results (141-150 of 242) with videos related to
Sort By:
Pageof 25
Journal of Pain and Symptom Management|May 16, 2017
Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer FatigueCarolina X Sandler, David Goldstein, Sarah Horsfield, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 5, 2022
Interobserver and intraobserver variability of RECIST assessment in ovarian cancerMichael Krasovitsky, Yeh Chen Lee, Hao-Wen Sim, et al.Journal of the National Cancer Institute|August 16, 2011
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancerChee K Lee, Michael Friedlander, Chris Brown, et al.Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.JCO Oncology Practice|January 14, 2026
Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology RegistryMahendra Naidoo, Orla McNally, Clare L Scott, et al.Human Reproduction (Oxford, England)|April 21, 2016
Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutationsKelly-Anne Phillips, Ian M Collins, Roger L Milne, et al.British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort studyDavid Goldstein, Barbara K Bennett, Kate Webber, et al.Gynecologic Oncology|August 24, 2018
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group studyAlexander B Olawaiye, James J Java, Thomas C Krivak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationBella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, et al.Pageof 25